EDANUR TOPALAN

Mrs. EDANUR TOPALAN

Ecology and Genetics, University of Oulu, Oulu, Pohjois-Pohjanmaa, Finland
orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 February 2025 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
FRFarida Reymova
Farida Reymova
Belgin SeverBelgin Sever
Belgin Sever
ETEDANUR TOPALAN
EDANUR TOPALAN
CSCanan Sevimli-Gur
Canan Sevimli-Gur
MCMustafa Can
Mustafa Can
Halilibrahim CiftciHalilibrahim Ciftci
Halilibrahim Ciftci
Background: Despite recent breakthroughs in cancer treatment, non-small cell lung cancer (NSCLC) and breast cancer remain major causes of death from all malignancies. The epidermal growth factor receptor (EGFR) is an important mediator of the pathways involved in cell proliferation, apoptosis, and angiogenesis. Thus, its overexpression triggers several types of cancer, including NSCLC and breast cancer. Methods: In the current study, we synthesized new pyrimidine-tethered compounds (chalcone derivative (B-4), pyrazoline–carbothioamide (B-9), and pyrazoline–thiazole hybrids (BH1-7)). These compounds were then tested for cytotoxicity against A549 NSCLC and MCF-7 breast cancer cells. Results: Of these, B-4 displayed significant cytotoxicity against both cells (IC50 = 6.70 ± 1.02 µM for MCF-7; IC50 = 20.49 ± 2.7 µM for A549) compared to the standard agent lapatinib (IC50 = 9.71 ± 1.12 µM for MCF-7; IC50 = 18.21 ± 3.25 µM for A549). The anticancer potential of B-4 between Jurkat leukemic T cells and peripheral blood mononuclear cells (PBMCs) (healthy) was found to be selective. Mechanistically, 11.9% and 10.2% of A549 and MCF-7 cells treated with B-4, respectively, underwent apoptosis and B-4 produced 46% EGFR inhibition at a concentration of 10 μM. The B-4/EGFR complex obtained after induced fit docking was subjected to 300 ns of molecular dynamics simulation, which confirmed the stability of the complex in a mimicked biological environment. On the other hand, B-4 was shown to have drug-like properties by in silico pharmacokinetic estimation. Conclusions: B-4 is an EGFR inhibitor and apoptosis inducer for future NSCLC and breast cancer studies.

7 April 2025 in Archiv der Pharmazie
Verified
Journal Article
Open access
ETEDANUR TOPALAN
EDANUR TOPALAN
ABAhmet Büyükgüngör
Ahmet Büyükgüngör
MÇMelih Çiğdem
Melih Çiğdem
SGSinan Güra
Sinan Güra
Belgin SeverBelgin Sever
Belgin Sever
Halilibrahim CiftciHalilibrahim Ciftci
Halilibrahim Ciftci
The epidermal growth factor receptor (EGFR) family, comprising receptor tyrosine kinases (RTK) such as EGFR and HER2, plays a critical role in various signaling pathways related to cell proliferation, differentiation, and growth. EGFR overactivation due to aberrant signaling can lead to various cancers, including non‐small cell lung cancer (NSCLC). To develop treatment for EGFR‐related NSCLC, several tyrosine kinase inhibitors (TKIs) were designed: gefitinib, erlotinib, as first‐generation; neratinib, dacomitinib as second‐generation; osimertinib, lazertinib as third‐generation, as examples. However, due to the acquired resistance by the mutations such as EGFRT790M and EGFRC797S together with the exon 20 insertion mutations, these drugs do not provide promising results for NSCLC patients. The development of fourth‐generation inhibitors like EAI045 and further innovative drugs to overcome this resistance problem is a must to cure EGFR‐related NSCLC. Among these, pyrazoline‐thiazole scaffolds are found effective as EGFR‐HER2 inhibitors against NSCLC, making them promising drug candidates. Although structures obtained so far for the EGFR family provide meaningful insights into the mechanisms, the quality and the quantity of the EGFR family structures are insufficient to elucidate the complete structures and functions to overcome NSCLC. This review evaluates the structures of EGFR‐HER2 and investigates their relation to NSCLC.

3 June 2025 in bioRxiv
Verified
Preprint
Open access
PDF file
ETEDANUR TOPALAN
EDANUR TOPALAN
Halilibrahim CiftciHalilibrahim Ciftci
Halilibrahim Ciftci
Hasan DeMirciHasan DeMirci
Hasan DeMirci
The human epidermal growth factor receptor 2 tyrosine kinase domain (HER2-TKD) plays a central role in signal transduction and is a significant therapeutic target in cancer. This study aimed to produce soluble recombinant HER2-TKD in Escherichia coli to enable structural studies for drug screening applications. The HER2-TKD gene was cloned into the pET28a(+) expression vector and expressed in E. coli. Initial expression led to the formation of inclusion bodies; thus, sarcosyl was used to solubilize the aggregated protein. Several induction durations were tested to optimize soluble expression. SDS-PAGE analysis was used to monitor expression and solubilization efficiency. The recombinant protein was purified using size-exclusion chromatography and reverse affinity chromatography to remove the SUMO tag. Crystallization trials were initiated using commercial screens to obtain diffraction-quality crystals. Soluble HER2-TKD was successfully obtained after optimization of induction and solubilization conditions. Crystallization efforts are ongoing to improve crystal quality for future structural analysis. These results provide a foundation for structure-based drug discovery studies targeting HER2.

22 January 2026 in Türk Tarım ve Doğa Bilimleri Dergisi
Verified
Journal Article
Closed access
ETEDANUR TOPALAN
EDANUR TOPALAN
Halilibrahim CiftciHalilibrahim Ciftci
Halilibrahim Ciftci
Hasan DeMirciHasan DeMirci
Hasan DeMirci
The epidermal growth factor receptor tyrosine kinase domain (EGFR-TKD) is a key regulator of intracellular signaling events that control cell proliferation. Aberrant EGFR activation is closely associated with the development of non-small cell lung cancer (NSCLC). In this study, recombinant EGFR-TKD was expressed in Escherichia coli Rosetta™ 2 (DE3) cells using a pET28a(+) expression plasmid carrying an N-terminal 6×His-SUMO- tag. During expression, a large proportion of the protein accumulated in inclusion bodies; therefore, we employed a solubilization approach. Treatment with 1.5% sarcosyl reproducibly yielded a soluble protein fraction compatible with subsequent purification steps. Optimizing induction parameters, including temperature, IPTG concentration, and expression duration, improved both the yield and solubility of the protein. Following size-exclusion chromatography, the monomeric protein fraction was isolated and used for crystallization trials, which resulted in the formation of small but well-defined microcrystals under several conditions. Although these crystals did not yet provide diffraction suitable for structure determination, their reproducible appearance indicates that the obtained EGFR-TKD is structurally competent for crystallization trials. Overall, the workflow establishes a practical and reproducible bacterial expression and purification strategy that forms a basis for continued crystallization optimization and structure-based inhibitor development targeting EGFR-driven cancers.

3 June 2025 in bioRxiv
Verified
Preprint
Open access
PDF file
ETEDANUR TOPALAN
EDANUR TOPALAN
Halilibrahim CiftciHalilibrahim Ciftci
Halilibrahim Ciftci
Hasan DeMirciHasan DeMirci
Hasan DeMirci
Background and Aim The Epidermal Growth Factor Receptor Tyrosine Kinase Domain (EGFR-TKD) plays a key role in regulating cell growth and is closely linked to cancer progression. In this study, we set out to produce, purify, and crystallize recombinant EGFR-TKD in order to create a solid foundation for future drug screening and structure-based research. Materials and Methods We used pET28a(+) plasmid and expressed EGFR-TKD in Escherichia coli. At first, most of the protein ended up in inclusion bodies, but with the help of sarcosyl, we were able to solubilize it effectively. To improve the amount and quality of the protein, we optimized several expression conditions, including temperature, inducer concentration, and induction time. The purification process included size-exclusion chromatography and a reverse affinity step to remove the SUMO tag, resulting in protein suitable for crystallization Results Following successful optimization, soluble EGFR-TKD was obtained, and initial crystals were successfully grown under defined conditions. These crystals represent a promising starting point for drug screening applications, providing a structural platform that can be further refined to support the discovery and development of novel EGFR inhibitors. Conclusion This study presents an effective strategy for the production, purification, and initial crystallization of recombinant EGFR-TKD. The established workflow lays a solid foundation for future drug screening efforts and structural investigations targeting EGFR.